Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development
Aims To Commercialize Its Own Products
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
